NCT04009265 is a Phase 3 clinical trial of adjuvant treatment in Esophageal Squamous Cell Carcinoma, sponsored by Fujian Medical University Union Hospital.

Who is sponsoring NCT04009265?

NCT04009265 is sponsored by Fujian Medical University Union Hospital.

What drugs are being tested in NCT04009265?

Interventions in NCT04009265: adjuvant treatment.

What condition does NCT04009265 study?

NCT04009265 studies Esophageal Squamous Cell Carcinoma.

Is NCT04009265 still recruiting?

NCT04009265 is currently recruiting now. Last updated 12 November 2021.

Last reviewed 2021-11-12 · How we verify

NCT04009265

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma

Recruiting now Phase 3 Last updated 12 November 2021

What this trial tests

Phase 3 trial testing adjuvant treatment in Esophageal Squamous Cell Carcinoma in 819 participants. Currently enrolling.

Timeline

23 August 2019

Primary endpoint
1 July 2022

1 July 2027

Quick facts

Lead sponsor	Fujian Medical University Union Hospital
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	819
Start date	23 August 2019
Primary completion	1 July 2022
Estimated completion	1 July 2027
Sites	1 location across China

Drugs / interventions tested

adjuvant treatment — full drug profile →

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Fujian Medical University Union Hospital

Who can join

Adults 18 to 75, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multi-center prospective randomized controlled study was conducted to compare the effects of adjuvant chemotherapy, chemoradiotherapy and surgery alone for the patients with esophageal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other Fujian Medical University Union Hospital trials

Trials by the same sponsor.

NCT07406815 — The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Inva · Phase 3 · not yet recruiting
NCT07444983 — Rezvilutamide for High-Risk Prostate Cancer After Surgery · NA · not yet recruiting
NCT07493070 — Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca · NA · active not recruiting
NCT07389889 — Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nod · NA · not yet recruiting
NCT07303231 — The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esoph · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04009265 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University Union Hospital
Last refreshed: 12 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04009265.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing